BIO to Senate Judiciary: Stop Abuses at PTO

BIO to Senate Judiciary: Stop Abuses at PTO

Gamesmanship of the United States Patent and Trademark Office’s (PTO) Inter Partes Review (IPR) process by an oddball assortment of generic drug makers, short-sellers and blackmailers has exposed legitimate patent holders to the un-American threat of double, triple or unlimited jeopardy.

BIO President and CEO James C. Greenwood today called upon Senate Judiciary Committee Chairman Grassley and Ranking Member Feinstein to adequately correct these deficiencies at the USPTO that are undermining the longstanding and carefully-balanced procedures laid out by the highly successful Hatch-Waxman Act.

IPR undermines the long-established, bi-partisan Hatch-Waxman framework that allows for legitimate patent questions to be litigated in the open in federal court.  Congress must act to keep innovation moving forward and intellectual property safe for everyone.

Click here to read the letter to the Senate Committee on Judiciary regarding deficiencies at the USPTO

Filed under: Patently BIOtech, , , , ,